|
IC-VEC Ltd is a biotechnology company that specializes in the research and development of non-viral drug delivery systems. The company's therapeutic area of concentration is cancer and liver disease. IC-VEC plans to use its technology to develop animal health, DNA based, and cancer vaccines. The firm was a 2001 spin-off from the Imperial College Genetics Therapies Centre.
|
| | | Contact Information | |
Address: |
13 Prince's Gardens
London SW7 1NA, United Kingdom
| | Phone: | +44-20-7594-1057 | | Fax: | +44-20-7594-1061 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman:
Andrew Miller
| | • |
CEO:
Matthew Speers
| | • |
CFO:
Akihisa Furuno
|
|
|
